Adc Therapeutics SA
Open
$3.77
Prev. Close
$3.76
High
$3.78
Low
$3.77
Market Snapshot
$468.26M
-3.3
-1.63
$70.84M
188
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 188 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
emptyResult
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 188 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Recently from Cashu
ADC Therapeutics SA Launches Employee Inducement Plan to Attract Top Talent
ADC Therapeutics Strengthens Workforce with New Employee Inducement Plan On April 1, 2025, ADC Therapeutics SA, a prominent player in the field of antibody drug conjugates (ADCs), announces the grant…
ADC Therapeutics SA: Pioneering Innovative Antibody Drug Conjugates for Cancer Treatment
Innovative Approaches in Antibody Drug Conjugate Development: ADC Therapeutics' Ongoing Commitment ADC Therapeutics SA, a prominent leader in the field of antibody drug conjugates (ADCs), is making st…
ADC Therapeutics SA Expands Workforce to Drive Cancer Treatment Innovation
ADC Therapeutics Strengthens Its Workforce to Propel Innovation in Cancer Treatment ADC Therapeutics SA, a trailblazer in the antibody drug conjugates (ADCs) field, announces the grant of stock option…
ADC Therapeutics SA Reports Promising DLBCL Trial Results and Strategic Advancements
ADC Therapeutics Advances in Clinical Trials for DLBCL Treatment ADC Therapeutics SA (NYSE: ADCT) makes significant strides in the field of oncology with promising updates from its clinical trials, pa…